Abbott Laboratories $ABT Shares Sold by West Branch Capital LLC

West Branch Capital LLC decreased its stake in Abbott Laboratories (NYSE:ABT) by 83.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,576 shares of the healthcare product maker’s stock after selling 13,061 shares during the period. West Branch Capital LLC’s holdings in Abbott Laboratories were worth $234,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in ABT. J. Stern & Co. LLP lifted its stake in Abbott Laboratories by 12,439.6% in the fourth quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock valued at $4,926,279,000 after buying an additional 39,005,451 shares during the last quarter. Norges Bank bought a new stake in Abbott Laboratories in the 4th quarter valued at about $2,938,892,000. Arrowstreet Capital Limited Partnership boosted its stake in Abbott Laboratories by 217.0% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 5,522,222 shares of the healthcare product maker’s stock valued at $566,967,000 after purchasing an additional 3,780,402 shares during the period. Assenagon Asset Management S.A. grew its position in Abbott Laboratories by 303.0% in the 1st quarter. Assenagon Asset Management S.A. now owns 4,429,571 shares of the healthcare product maker’s stock worth $454,784,000 after purchasing an additional 3,330,368 shares during the last quarter. Finally, Ninety One UK Ltd acquired a new position in shares of Abbott Laboratories during the fourth quarter worth approximately $336,815,000. 75.18% of the stock is currently owned by institutional investors.

Abbott Laboratories Trading Up 1.0%

Shares of Abbott Laboratories stock opened at $109.70 on Wednesday. The business has a fifty day simple moving average of $96.38 and a 200-day simple moving average of $99.71. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $137.49. The firm has a market cap of $189.82 billion, a price-to-earnings ratio of 35.50, a price-to-earnings-growth ratio of 2.10 and a beta of 0.59. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, topping the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The firm had revenue of $12.59 billion for the quarter, compared to analysts’ expectations of $12.52 billion. During the same period in the previous year, the business earned $1.26 earnings per share. Abbott Laboratories’s revenue for the quarter was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, equities analysts forecast that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date is Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 81.55%.

Wall Street Analyst Weigh In

Several analysts have weighed in on ABT shares. Wells Fargo & Company lifted their target price on Abbott Laboratories from $109.00 to $112.00 and gave the company an “overweight” rating in a research note on Friday, July 17th. TD Cowen reissued a “buy” rating and set a $115.00 price target on shares of Abbott Laboratories in a report on Friday, July 17th. Raymond James Financial cut their price objective on shares of Abbott Laboratories from $130.00 to $115.00 and set an “outperform” rating on the stock in a research note on Friday, April 17th. Citigroup increased their target price on shares of Abbott Laboratories from $108.00 to $112.00 and gave the company a “buy” rating in a research report on Friday, July 17th. Finally, JPMorgan Chase & Co. raised their target price on shares of Abbott Laboratories from $110.00 to $120.00 and gave the company an “overweight” rating in a research note on Friday, July 17th. Three analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, Abbott Laboratories presently has an average rating of “Moderate Buy” and an average target price of $118.17.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.